Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

TAR DNA‐binding protein 43 (TDP‐43) contributes to the mismatch between medial temporal volumes and flortaucipir uptake in elderly patients with Alzheimer’s disease neuropathologic changes
Tosakulwong, Nirubol , Weigand, Stephen D. , Petersen, Ronald C. , Reichard, Ross R., Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Carlos, Arenn F. , Senjem, Matthew L. , Schwarz, Christopher G. , Knopman, David S. , Boeve, Bradley F. , Nguyen, Aivi T. , Dickson, Dennis W. , Jack, Clifford R. , Whitwell, Jennifer L.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.067468 Get It

AbstractBackgroundWe previously demonstrated that Alzheimer’s disease (AD) patients ≥70 y/o tend to have smaller medial temporal volumes in the presence of relatively less medial temporal 18F‐flortaucipir‐PET uptake compared to young AD patients. TAR DNA‐binding protein 43 (TDP‐43) is frequently found in the brains of AD patients and is associated with old age and medial temporal atrophy. In this study, we aimed to determine whether TDP‐43 could be contributing to the mismatch between medial temporal volumes and flortaucipir‐PET uptake in older AD patients.MethodWe identified 77 participants (median age at death 79 years [range: 51‐99]) who had been enrolled into the Mayo Clinic Alzheimer’s Disease Research Center or Neurodegenerative Research Group (NRG), had undergone flortaucipir‐PET and volumetric MRI scans close to death, and autopsy confirmed AD neuropathological changes, as well as TDP‐43 assessments. Grey matter volumes and flortaucipir standard uptake value ratios (SUVRs) were calculated for hippocampus, amygdala, entorhinal, inferior temporal, and midfrontal cortices. We used bivariate‐response linear regression modelling, adjusting for Braak neurofibrillary tangle stage, to estimate the effect of TDP‐43 and age on gray matter volume and flortaucipir uptake, and tested whether TDP‐43 effect sizes varied according to age.ResultAfter accounting for Braak stage, older individuals tended to have significantly lower flortaucipir uptake across regions and lower hippocampal and entorhinal cortex (ERC) volumes. TDP‐43 was associated with reduced hippocampus and ERC volumes but was unrelated to flortaucipir SUVRs (Figure 1). Notably, the TDP‐43 effect size for the hippocampus and ERC was largely consistent across age, i.e., at any age, TDP‐43‐positive participants had significantly smaller hippocampal (∼12% decrease) and ERC (13% decrease) volumes than TDP‐43‐negative participants. However, at older ages, the mean volumes in the whole cohort and, more evidently, in those with dementia moved closer towards the mean of those with TDP‐43 (Figure 1), likely attributable to the increasing frequency of TDP‐43 with age.ConclusionTDP‐43 is a major contributor to the mismatch between flortaucipir uptake and medial temporal lobe volumes in older AD patients where lower medial temporal regional volumes are observed in the presence of less flortaucipir uptake.
Investigation of differentially expressed proteins through neurofibrillary tangle maturation in Alzheimer’s disease using NanoString’s GeoMx Digital Spatial Profiler
Wickland, Daniel P. , Lesser, Elizabeth R. , Kachergus, Jennifer M., Graff‐Radford, Neill R. , Thompson, E. Aubrey , Moloney, Christina M. , Liu, Chia‐Chen , Blitterswijk, Marka van , Dickson, Dennis W. , Murray, Melissa E.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.066668 Get It

AbstractBackgroundNeurofibrillary tangles are dynamic entities with a lifespan encompassing three maturity levels: intracellular pretangles, intracellular mature tangles, and extracellular ghost tangles. Proteins are suggested to be differentially expressed throughout the tangle lifespan; however, past studies may be limited by spatial expression or number of proteins investigated. We sought to assess differences in protein expression across the tangle lifespan using GeoMxTM Digital Spatial Profiler (DSP) by NanoString, a new technology allowing for spatially derived multiplex investigation.MethodWe used DSP to measure protein expression in hippocampi from Alzheimer’s disease (n=6) and nondemented controls (n=2) using the “Human Neural Cell Profiling Core” and “Alzheimer’s Pathology” module. Regions of interest (ROIs) were classified by the major tangle maturity level recognized by a primary fluorescent conjugated tau antibody. Protein expression was normalized to the geomean of the three housekeeping genes. The tau‐positive segment was specifically analyzed for comparisons. ANOVA was used for group‐wise comparisons and t‐test using the Benjamini‐Yekutieli adjustment for multiple tests was used for pair‐wise comparisons.ResultAs expected, cytoskeletal (e.g., MAP2, Tau) and neuronal (e.g., NeuN) markers generally decreased through the neurofibrillary tangle lifespan (Figure). Markers profiled as neurodegenerative (e.g., amyloid‐β1‐42, APOE, APP) generally increased through tangle maturity levels, except for TDP‐43 which decreased. Interestingly, there was no significant difference in ubiquitin expression. Astrocytic GFAP and S100B expression was significantly increased through each maturity level. Expression of microglial‐specific markers P2RY12 and TMEM119 was significantly elevated in ghost tangles compared to mature tangles. Additional microglial/macrophage markers including Iba‐1 and CD68 were generally increased as neurofibrillary tangles matured. Interestingly, APOE expression remained low in pretangles and mature tangles before dramatically increasing in ghost tangles (Figure).ConclusionOur findings suggest that proteins are differentially expressed throughout the tangle lifespan and the majority followed a monotonically directed pattern. Non‐monotonically directed protein patterns may reflect the death of the neuron during the ghost tangle maturity level. Future studies will test the hypothesis that the microenvironment of the hippocampus is altered with increasing vulnerability to tangle pathology.
Regional white matter hyperintensities in posterior cortical atrophy and logopenic progressive aphasia
Pham, Nha Trang Thu, Radford, Jonathan Graff, Spychalla, Anthony J., Lowe, Val J. , Vemuri, Prashanthi , Josephs, Keith A. , Whitwell, Jennifer L., Vemuri, Prashanthi , Machulda, Mary M. , Schwarz, Christopher G. , Senjem, Matthew L. , Jack, Clifford R. , Whitwell, Jennifer

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S1 | Pages: No page available

10.1002/alz.064596 Get It

AbstractBackgroundWhite matter hyperintensities (WMH) are markers of cerebral small vessel disease and have been associated with higher risk of typical amnestic Alzheimer’s disease (AD), however, little is known about the role of WMHs in atypical variants of AD. This study aimed to determine the frequency and distribution of WMH in two atypical variants of AD: logopenic progressive aphasia (LPA) and posterior cortical atrophy (PCA), and determine whether WMH are associated with demographic and clinical outcomes in these cohorts.MethodSeventy‐five LPA and 39 PCA patients were recruited by the Neurodegenerative Research Group and underwent two‐ dimensional fluid‐attenuated inversion recovery (FLAIR) MRI and Pittsburgh Compound B (PiB) PET. All patients were PiB‐positive. All FLAIR images were segmented using an in‐house software, then were manually edited by a trained imaging analyst. WMH volume was scaled by total intracranial volume to correct for differences in head size. Adjusted WMH burdens were compared between LPA and PCA, and associations were assessed between WMH burden and age, global PiB standard uptake value ratios (SUVRs), and clinical metrics, including tests of general cognitive impairment, executive function, naming, repetition, visuospatial and visuoperceptual function, and parkinsonism. Associations between WMHs and clinical scores were adjusted for age and brain volume to correct for atrophy.ResultTotal WMH burden was similar in PCA and LPA, however, regional differences were identified with PCA having greater subcortical WMH burden in right occipital, parietal, and temporal lobes compared to LPA, and LPA having greater WMH burden in left deep grey and white matter and greater subcortical burden in left parietal lobe compared to PCA. Total WMH burden was greater with older age in both groups but was not related to global PiB SUVR either globally or locally. Greater total WMH was associated with visuoperceptual performance in both cohorts after correcting for atrophy. When assessed regionally, visuoperceptual performance was associated with right subcortical occipital WMH across the cohort.ConclusionRegional distribution of WMHs differ across clinical variants of atypical AD and WMHs may impact clinical outcomes, although further work is needed to determine whether they reflect cerebrovascular disease or regionally specific neurodegenerative changes.
Altered functional connectivity networks in logopenic progressive aphasia and posterior cortical atrophy
Graff‐Radford, Jonathan, Sintini, Irene , Gunter, Jeffrey L. , Lowe, Val J. , Josephs, Keith A. , Whitwell, Jennifer L. , Singh, Neha Atulkumar , Graff‐Radford, Jonathan , Machulda, Mary M. , Botha, Hugo , Jones, David T. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S1 | Pages: No page available

10.1002/alz.063393 Get It

AbstractBackgroundResting state functional connectivity (rsfMRI) studies have shown functional network disruptions in logopenic progressive aphasia (LPA) (reduced connectivity within the left temporal language network) and posterior cortical atrophy (PCA) (reduced connectivity within ventral visual network). However, little is known about how these networks compare and how connectivity differs within and between networks in these atypical Alzheimer’s Disease (AD) phenotypes.MethodFifty‐nine amyloid‐positive PCA patients and eighty‐five amyloid‐positive LPA patients were recruited by the Neurodegenerative Research Group at Mayo Clinic, Rochester, MN, and underwent structural and resting state functional MRI. Spatially preprocessed data was analyzed using the CONN functional connectivity toolbox to explore the default mode network (DMN), salience, sensorimotor, left language, visual and memory networks, which were generated by averaging multiple regions‐of‐interest (ROI) within each network. The data was analyzed at both the voxel‐level and network‐level (ROI‐ROI).ResultVoxel‐level differences in functional connectivity between PCA and LPA were observed in all networks (p<0.05; cluster size, FWE=0.05). PCA showed reduced connectivity in the occipital lobe in visual and memory networks, parietal lobe in language and DMN, and sensorimotor strip in sensorimotor network, particularly on the right, compared to LPA. Conversely, LPA showed reduced connectivity in the frontal cortex in salience, memory, visual and sensorimotor networks, inferior parietal lobe in visual network, and anterior temporal pole and sensorimotor cortex in the language network, compared to PCA. Between network differences (p<0.05; cluster size, FDR=0.05) were observed between groups, with PCA showing reduced connectivity between the visual and sensorimotor networks, while LPA showed reduced connectivity between the language and sensorimotor networks. The DMN was anti‐correlated to the language network in PCA, while it was positively correlated to the language network in LPA. In both phenotypes, the DMN was anticorrelated with the salience network. The visual network in PCA showed connections to all networks, while in LPA, it was only connected to the salience, language and DMN.ConclusionThe atypical AD phenotypes were associated with multiple disruptions in connectivity, both within and between brain networks. Phenotype specific differences in connectivity patterns were noted in visual network for PCA and language network for LPA.
Unique brain iron profiles associated with logopenic progressive aphasia and posterior cortical atrophy
Graff‐Radford, Jonathan, Martin, Peter , Shu, Yunhong , Petersen, Ronald C. , Lowe, Val J. , Josephs, Keith A. , Whitwell, Jennifer L., Singh, Neha Atulkumar , Arani, Arvin , Graff‐Radford, Jonathan , Senjem, Matthew L. , Schwarz, Christopher G. , Cogswell, Petrice M. , Knopman, David S. , Jack, Clifford R. , Whitwell, Jennifer

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S1 | Pages: No page available

10.1002/alz.063271 Get It

AbstractBackgroundQuantitative susceptibility mapping (QSM) can detect iron distribution in the brain by estimating the local tissue magnetic susceptibility of every voxel. Dysregulation of neuronal iron has been correlated with typical Alzheimer’s disease (tAD), but little is known about iron distribution in atypical clinical presentations of AD such as logopenic progressive aphasia (LPA) and posterior cortical atrophy (PCA).MethodEleven PCA patients and eight LPA patients were recruited by the Neurodegenerative Research Group at Mayo Clinic, Rochester, MN, and underwent MRI that included a five‐echo gradient echo sequence for calculation of QSM. Mean QSM signal was extracted from gray and white matter for regions‐of‐interest across the brain using the Mayo Clinic Adult Lifespan Template. Hierarchical models were fit per‐region and per‐hemisphere to compare PCA and LPA to each other, to 20 healthy controls, and to 20 patients with tAD recruited by the Alzheimer’s Disease Research Center.ResultStrong evidence (posterior probability>0.99) was observed for greater susceptibility in the left middle occipital gyrus and amygdala in both LPA and PCA, and in the right precuneus and inferior temporal gyrus in PCA compared to controls. Moderate evidence for greater susceptibility (posterior probability>0.90) was also observed in the left insula, inferior occipital gyrus, entorhinal cortex, and right inferior parietal gyrus and amygdala in both LPA and PCA, along with right angular gyrus and middle occipital gyrus in PCA and right insula and caudate in LPA, when compared to controls. Comparing between phenotypes, LPA showed moderate evidence for greater susceptibility in the caudate, hippocampus, substantia nigra, left supramarginal gyrus and posterior cingulate compared to PCA, while PCA showed greater susceptibility in the right precuneus compared to LPA. Both LPA and PCA showed moderate‐strong evidence for greater susceptibility than tAD, particularly in medial and lateral parietal regions.ConclusionUnique iron profiles were identified in LPA and PCA within cortical and subcortical structures. These changes are in line with disease‐related neurodegenerative changes in the clinical phenotypes, suggesting that QSM could be an informative marker to study iron deposition in these patients.
Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical Trials
Foster, Jared C. , Lichtman, Stuart M. , Perlmutter, Jane , Extermann, Martine , Dodd, Kevin W. , Tew, William P. , Sedrak, Mina S. , Jatoi, Aminah , Little, Richard F. , Lichtman, Stuart M , Sedrak, Mina S. , Le‐Rademacher, Jennifer , Mohile, Supriya G. , Unger, Joseph M. , Hudson, Matthew Francis , Dotan, Efrat , Klepin, Heidi D. , Wildes, Tanya M.

Mayo Clinic

JNCI Monographs | December 15, 2022 | Volume: 2022 | Issue: 60 | Pages: 135-141

10.1093/jncimonographs/lgac023 | PMID 36519818 Get It

AbstractAlthough adults aged 65 years or older make up a strong majority of cancer patients, their underrepresentation in cancer clinical trials leads to the lack of representative data to guide evidence-based therapeutic decisions in this patient population. The Trial Design Working Group, convened as part of the workshop titled, Engaging Older Adults in the National Cancer Institute Clinical Trials Network: Challenges and Opportunities, recommended study designs and design elements that could improve accrual of older adults in National Cancer Institute–funded clinical trials. These include trials that are specifically designed to enroll older adults, trials that include a cohort of older patients (parallel cohort, stratified cohort, or embedded cohort), and trials with pragmatic design elements to facilitate enrollment of older adults. This manuscript provides brief descriptions of the recommended designs, examples of successful trials, and considerations for implementation of these designs.As with any clinical trial, the scientific questions and trial objectives should drive the study design, the selection of endpoints and intervention, and eligibility criteria. When designing trials that include older adults, the heterogeneity of fitness levels is an important consideration as fitness can influence accrual rates and outcomes. Appropriately incorporating geriatric assessments can help identify the optimal subset of older patients for inclusion and minimize selection bias. Incorporating pragmatic design elements to reduce the burden on trial participants as well as on accruing sites and retaining essential elements to ensure that the main goal of the trial can be accomplished can enhance enrollment without compromising the integrity of trials.
Integrating Geriatric Assessment Measures into National Cancer Institute Clinical Trials
Magnuson, Allison , Walde, Noam Van der, McKoy, June M. , Little, Richard F. , Klepin, Heidi D. , Klepin, Heidi D , Wildes, Tanya M. , Wong, Melisa L. , Le‐Rademacher, Jennifer

Mayo Clinic

JNCI Monographs | December 15, 2022 | Volume: 2022 | Issue: 60 | Pages: 142-150

10.1093/jncimonographs/lgac021 | PMID 36519816 Get It

AbstractTo improve the care of older adults with cancer, the traditional approach to clinical trial design needs to be reconsidered. Older adults are underrepresented in clinical trials with limited or no information on geriatric-specific factors, such as cognition or comorbidities. To address this knowledge gap and increase relevance of therapeutic clinical trial results to the real-life population, integration of aspects relevant to older adults is needed in oncology clinical trials. Geriatric assessment (GA) is a multidimensional tool comprising validated measures assessing specific health domains that are more frequently affected in older adults, including aspects related to physical function, comorbidity, medication use (polypharmacy), cognitive and psychological status, social support, and nutritional status. There are several mechanisms for incorporating either the full GA or specific GA measures into oncology therapeutic clinical trials to contribute to the overarching goal of the trial. Mechanisms include utilizing GA measures to better characterize the trial population, define trial eligibility, allocate treatment receipt within the context of the trial, develop predictive models for treatment outcomes, guide supportive care strategies, personalize care delivery, and assess longitudinal changes in GA domains. The objective of this manuscript is to review how GA measures can contribute to the overall goal of a clinical trial, to provide a framework to guide the selection and integration of GA measures into clinical trial design, and ultimately enable accrual of older adults to clinical trials by facilitating the design of trials tailored to older adults treated in clinical practice.
2216. ROAR ED-SANE: A Retrospective Observational Assessment Review of an Emergency Department Sexual Assault Nurse Examiner Program’s Adherence to CDC Guidelines for Sexually Transmitted Infections
Nelson, Jennifer , Woolever, Nathan L. , Meyer, Lisa M, Hall, Scott T. , Stakston, Jaclyn , Sistine, Michael Van, Tempelis, Jennifer, Dierkhising, Ross , Roush, Kathleen , Dababneh, Ala S. , Lessard, Sarah

Mayo Clinic

Open Forum Infectious Diseases | December 15, 2022 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofac492.1835 Get It

Abstract Background Sexual assault survivors are at increased risk for sexually transmitted infections. Due to patient vulnerability, institutions have implemented Sexual Assault Nurse Examiner (SANE) protocols to care for these patients. These protocols guide evidence collection, testing, treatment, and medical follow-up to ensure optimization of sexually transmitted infections (STIs) treatment, monitoring and follow-up. Previous gap analyses have identified decreased prescribing of prophylactic STI medications and scheduling follow-up appointments compared to guideline recommendations. The purpose of this study was to assess adherence of medication prescribing and follow-up scheduling practices to Centers for Disease Control (CDC) guidelines. Methods This study was a single-center, retrospective, observational, descriptive assessment which evaluated adherence rates to CDC guidelines, to scheduling medical follow-up, and patient attendance at scheduled appointments. Pediatric and adult patients who presented to the emergency department at Mayo Clinic Health System in La Crosse, WI from January 2018 through December 2021 were included. Data collected through chart review included demographics and laboratory data necessary for prescribing prophylactic HIV medications, antibiotics for STIs, emergency contraception, and vaccine administration. Descriptive statistics were used to evaluate results. Results One hundred three patients were evaluated. Majority of patients were female and presented within 3 days of assault. Medication adherence to CDC guidelines was ≥ 80% for chlamydia and gonorrhea whereas &lt; 80% was noted for trichomoniasis and HIV prophylaxis. Adherence to post-ED discharge follow-up was 40%. Conclusion Opportunities to improve adherence of ED-SANE protocols for medication prescribing and medical follow-up for trichomoniasis and HIV prophylaxis exist. Disclosures All Authors: No reported disclosures.
Local/Regional Recurrence Rates After Breast-Conserving Therapy in Patients Enrolled in Legacy Trials of the Alliance for Clinical Trials in Oncology (AFT-01)
Schumacher, Jessica R. , Wiener, Alyssa A. , Greenberg, Caprice C. , Edge, Stephen B. , Ruddy, Kathryn J. , Yang, Dou‐Yan , Havlena, Jeffrey , Neuman, Heather B. , Strand, Carrie , Hanlon, Bret M. , Partridge, Ann H. , Le‐Rademacher, Jennifer , Yu, Menggang , Vanness, David J.

Mayo Clinic

Annals of Surgery | December 15, 2022 | Volume: 277 | Issue: 5 | Pages: 841-845

10.1097/sla.0000000000005776 | PMID 36521077 Get It

Objective: We sought to evaluate local/regional recurrence rates after breast-conserving surgery in a cohort of patients enrolled in legacy trials of the Alliance for Clinical Trials in Oncology and to evaluate variation in recurrence rates by receptor subtype. Background: Multiple randomized controlled trials have demonstrated equivalent survival between breast conservation and mastectomy, albeit with higher local/regional recurrence rates after breast conservation. However, absolute rates of local/regional recurrence have been declining with multi-modality treatment. Methods: Data from 5 Alliance for Clinical Trials in Oncology legacy trials that enrolled women diagnosed with breast cancer between 1997 and 2010 were included. Women who underwent breast-conserving surgery and standard systemic therapies (n=4,404) were included. Five-year rates of local/regional recurrence were estimated from Kaplan-Meier curves. Patients were censored at the time of distant recurrence (if recorded as the first recurrence), death, or last follow-up. Multivariable Cox proportional hazards models were used to identify factors associated with time to local/regional recurrence, including patient age, tumor size, lymph node status, and receptor subtype. Results: Overall 5-year recurrence was 4.6% (95% CI=4.0-5.4%). Five-year recurrence rates were lowest in those with ER+ or PR+ tumors (Her2+ 3.4% [95% CI 2.0-5.7%], Her2- 4.0% [95% CI 3.2-4.9%]) and highest in the triple-negative subtype (7.1% [95% CI 5.4-9.3%]). On multivariable analysis, increasing nodal involvement and triple-negative subtype were positively associated with recurrence (P<0.0001). Conclusions: Rates of local/regional recurrence after breast conservation in women with breast cancer enrolled in legacy trials of the Alliance for Clinical Trials in Oncology are significantly lower than historic estimates. This data can better inform patient discussions and surgical decision-making.
1726. Patterns of Isavuconazole Use for Invasive Fungal Infections
Gow-Lee, Vanessa, Chesdachai, Supavit , Akhiyat, Nadia , Saleh, Omar Abu , Chesdachai, Supavit , Gow‐Lee, Vanessa J. , Gile, Jennifer , Harris, Courtney E.

Mayo Clinic

Open Forum Infectious Diseases | December 15, 2022 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofac492.1356 Get It

Abstract Background Isavuconazole (ISA) is a relatively recent triazole antifungal with several attractive qualities and so increased clinical experience and data on the use of ISA are desirable. However, the data on the pattern of ISA use in invasive fungal infections (IFI) is limited. Methods We conducted a retrospective study of patients with probable or proven IFI treated with ISA at Mayo Clinic from 1/1/2015 to 4/1/2020 to examine temporal trends and characteristics of ISA use. Results The use of ISA rose over this period, from 4 cases in 2015 to 42 cases in 2019. Of 131 patients identified, ISA was used as the initial antifungal in 15 (11.5%) patients and as the secondary agent in 116 (88.5%) patients. The most cited reasons for choosing ISA as first-line therapy were drug-drug interactions (5, 33%) and baseline QTc prolongation (3, 20%). In cases of ISA used as a secondary agent, the reasons for transitioning to ISA were QTc prolongation (22, 19%), followed by judged failure of the primary therapy (20, 17%), drug-drug interactions (12, 10%), and various toxicities with the first agent. ISA was discontinued early in 81 (62%) patients. Common reasons for early discontinuation were patient death or comfort care (27, 33%), intolerance (18, 22%), failure of therapy (17, 21%), cost or access (6, 7%), drug-drug interaction (3, 4%), issues with absorption or drug delivery (3, 4%), and microbe susceptibility (1, 1%). ISA was judged successful and used as definitive treatment in the remaining 50 (38%) patients. About 30 patients took &gt;1 year of ISA, and no major adverse effects from long-term therapy were noted. Conclusion Although ISA is approved for pulmonary aspergillosis and mucormycosis, we found that few patients were treated with ISA as either primary or salvage therapy. In cases where it was used, shortening the QTc and fewer drug-drug interactions were its most attractive qualities. Although it is a newer azole, the morbidity common with other antifungals should prompt more studies on ISA’s efficacy to increase clinicians’ confidence in this option. Disclosures All Authors: No reported disclosures.